MX2018010961A - Proteínas de fusión de unión a antígeno con dominios de proteína de choque térmico de 70 kilodaltons (hsp70) modificada. - Google Patents
Proteínas de fusión de unión a antígeno con dominios de proteína de choque térmico de 70 kilodaltons (hsp70) modificada.Info
- Publication number
- MX2018010961A MX2018010961A MX2018010961A MX2018010961A MX2018010961A MX 2018010961 A MX2018010961 A MX 2018010961A MX 2018010961 A MX2018010961 A MX 2018010961A MX 2018010961 A MX2018010961 A MX 2018010961A MX 2018010961 A MX2018010961 A MX 2018010961A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- antigen
- binding fusion
- domains
- modified
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 title 1
- 101150031823 HSP70 gene Proteins 0.000 title 1
- 101150052825 dnaK gene Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención se refiere a proteínas de fusión que comprenden un dominio de unión a antígeno fusionado con una proteína de choque térmico de 70 kilodaltons modificada; la invención además se refiere a métodos de uso de proteínas de fusión para inducir una respuesta inmunológica a antígenos y para tratar enfermedades asociadas con antígenos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662306168P | 2016-03-10 | 2016-03-10 | |
PCT/US2017/021911 WO2017156461A2 (en) | 2016-03-10 | 2017-03-10 | Antigen-binding fusion proteins with modified hsp70 domains |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018010961A true MX2018010961A (es) | 2019-03-28 |
Family
ID=59787756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018010961A MX2018010961A (es) | 2016-03-10 | 2017-03-10 | Proteínas de fusión de unión a antígeno con dominios de proteína de choque térmico de 70 kilodaltons (hsp70) modificada. |
Country Status (9)
Country | Link |
---|---|
US (2) | US20170260286A1 (es) |
EP (1) | EP3426289A4 (es) |
JP (1) | JP2019511246A (es) |
CN (1) | CN109562154A (es) |
AU (1) | AU2017229991A1 (es) |
CA (1) | CA3017356A1 (es) |
IL (1) | IL261681A (es) |
MX (1) | MX2018010961A (es) |
WO (1) | WO2017156461A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019534249A (ja) * | 2016-09-09 | 2019-11-28 | ザ ジェネラル ホスピタル コーポレイション | 癌の治療のための抗化学忌避剤とのhsp融合タンパク質 |
US11364264B2 (en) | 2016-09-09 | 2022-06-21 | The General Hospital Corporation | Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer |
EP3600395A4 (en) | 2017-03-23 | 2021-05-05 | The General Hospital Corporation | BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE |
CN109504698B (zh) * | 2017-09-15 | 2023-10-03 | 上海恒润达生生物科技股份有限公司 | 一种靶向全人源化mesothelin的嵌合抗原受体的方法和用途 |
CN111848819A (zh) * | 2020-07-31 | 2020-10-30 | 广东昭泰体内生物医药科技有限公司 | 一种靶向msln的嵌合抗原受体及其应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
PT761231E (pt) | 1992-06-25 | 2000-06-30 | Smithkline Beecham Biolog | Composicao de vacina contendo adjuvantes |
US5951988A (en) | 1993-03-30 | 1999-09-14 | University Of Saskatchewan | Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6194388B1 (en) | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
WO1997006828A1 (en) | 1995-08-18 | 1997-02-27 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious diseases and compositions useful in same |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
US7084256B2 (en) * | 1999-09-24 | 2006-08-01 | Large Scale Biology Corporation | Self antigen vaccines for treating B cell lymphomas and other cancers |
US6734173B1 (en) * | 1999-10-20 | 2004-05-11 | Johns Hopkins University | HSP DNA vaccines |
EP1253939B1 (en) * | 2000-01-14 | 2009-08-05 | Whitehead Institute For Biomedical Research | In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
AU2002212236A1 (en) * | 2000-09-13 | 2002-03-26 | Gabriele Multhoff | An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
GB0123756D0 (en) * | 2001-10-03 | 2001-11-21 | King S College London | A novel chaperone-type of adjuvant for vaccination - Basic 1 |
US20090162405A1 (en) * | 2006-12-14 | 2009-06-25 | Yong Qian | Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells |
WO2007054658A1 (en) * | 2005-11-14 | 2007-05-18 | King's College London | Control of immune responses |
HUE029919T2 (en) * | 2006-02-02 | 2017-04-28 | Massachusetts Gen Hospital | Genetically modified antibody stress protein fusions |
US7943133B2 (en) * | 2006-02-02 | 2011-05-17 | Boston Biocom Llc | Mesothelin antibody protein fusions and methods of use |
WO2007147898A1 (en) * | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Soluble heterodimeric receptors and uses thereof |
US7795411B2 (en) * | 2006-10-05 | 2010-09-14 | Fred Hutchinson Cancer Research Center | Vectors for expressing in vivo biotinylated recombinant proteins |
WO2013063419A2 (en) * | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
CN105481985A (zh) * | 2016-01-11 | 2016-04-13 | 王小平 | 一种热休克蛋白70功能肽与甲胎蛋白抗原表位肽复合物 |
-
2017
- 2017-03-10 MX MX2018010961A patent/MX2018010961A/es unknown
- 2017-03-10 US US15/456,196 patent/US20170260286A1/en not_active Abandoned
- 2017-03-10 CN CN201780029242.5A patent/CN109562154A/zh active Pending
- 2017-03-10 EP EP17764234.5A patent/EP3426289A4/en not_active Withdrawn
- 2017-03-10 WO PCT/US2017/021911 patent/WO2017156461A2/en active Application Filing
- 2017-03-10 JP JP2018567026A patent/JP2019511246A/ja active Pending
- 2017-03-10 CA CA3017356A patent/CA3017356A1/en active Pending
- 2017-03-10 AU AU2017229991A patent/AU2017229991A1/en not_active Abandoned
-
2018
- 2018-09-07 IL IL261681A patent/IL261681A/en unknown
-
2019
- 2019-08-05 US US16/532,200 patent/US11718683B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3426289A2 (en) | 2019-01-16 |
WO2017156461A3 (en) | 2017-10-05 |
CN109562154A (zh) | 2019-04-02 |
US20170260286A1 (en) | 2017-09-14 |
AU2017229991A1 (en) | 2018-10-04 |
EP3426289A4 (en) | 2019-08-07 |
JP2019511246A (ja) | 2019-04-25 |
US20200095332A1 (en) | 2020-03-26 |
IL261681A (en) | 2018-10-31 |
US11718683B2 (en) | 2023-08-08 |
CA3017356A1 (en) | 2017-09-14 |
WO2017156461A2 (en) | 2017-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018010961A (es) | Proteínas de fusión de unión a antígeno con dominios de proteína de choque térmico de 70 kilodaltons (hsp70) modificada. | |
IL271704A (en) | Targeted heterodimeric fc fusion proteins containing il-15/il-15rα and antigen binding domains | |
EA201790342A1 (ru) | Антитела к trem2 и способы их применения | |
HK1257518A1 (zh) | 針對人白介素-2的免疫刺激性人源化單克隆抗體及其融合蛋白 | |
PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
MX2018009581A (es) | Inmunoglobulina con fabs en tandem y sus usos. | |
MX2021001098A (es) | Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares. | |
FI4186920T3 (fi) | Ultrapitkävaikutteisia insuliini-Fc-fuusioproteiineja ja käyttömenetelmiä | |
CR20200171A (es) | Contorsbodies 2 + 1 biespecíficos | |
IL280102A (en) | Fusion protein containing PD1-4-1BBL and methods of using it | |
ZA201806450B (en) | Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses | |
WO2015198243A3 (en) | Compositions and methods for long acting proteins | |
EP3554544A4 (en) | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE | |
MX2018009389A (es) | Polipeptidos de union a la proteina a, anticuerpos anti-epha2 y metodos de uso de estos. | |
MA43717A (fr) | Anticorps anti-tnf et fragments fonctionnels de ceux-ci | |
IL280103A (en) | Fusion protein containing SIRPalpha-4-1BBL and methods of using it | |
ZA201805051B (en) | Egfl6 specific monoclonal antibodies and methods of their use | |
IL281413A (en) | Protein L for activation and expansion of immune cells with an adapted chimeric antigen receptor | |
MA43715A (fr) | Anticorps anti-tnf et fragments fonctionnels correspondants | |
PH12020552270A1 (en) | Anti-steap1 antigen-binding protein | |
PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins | |
MA43716A (fr) | Anticorps anti-tnf et fragments fonctionnels de ceux-ci | |
MA40536A (fr) | Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations | |
MX2021007421A (es) | Anticuerpo que se une a factor de crecimiento endotelial vascular (vegf) y a interleucina 1 beta (il-1beta) y metodos de uso. | |
AR100681A1 (es) | Moléculas multivalentes que comprenden dominios de unión de dr5 |